Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$43.39 - $51.63 $186,577 - $222,009
4,300 New
4,300 $217,000
Q4 2022

Feb 14, 2023

SELL
$37.12 - $46.52 $5,233 - $6,559
-141 Reduced 1.83%
7,569 $285,000
Q3 2022

Nov 14, 2022

BUY
$36.54 - $48.66 $281,723 - $375,168
7,710 New
7,710 $341,000
Q3 2021

Nov 15, 2021

SELL
$33.54 - $40.55 $450,576 - $544,748
-13,434 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$34.54 - $47.25 $464,010 - $634,756
13,434 New
13,434 $528,000
Q3 2020

Nov 16, 2020

SELL
$47.45 - $62.95 $208,352 - $276,413
-4,391 Closed
0 $0
Q2 2020

Aug 17, 2020

SELL
$46.85 - $61.05 $70,930 - $92,429
-1,514 Reduced 25.64%
4,391 $259,000
Q1 2020

May 15, 2020

SELL
$41.6 - $63.4 $342,617 - $522,162
-8,236 Reduced 58.24%
5,905 $279,000
Q4 2019

Feb 14, 2020

SELL
$53.85 - $65.27 $573,610 - $695,256
-10,652 Reduced 42.96%
14,141 $852,000
Q3 2019

Nov 14, 2019

SELL
$59.06 - $72.15 $28.3 Million - $34.6 Million
-479,149 Reduced 95.08%
24,793 $1.49 Million
Q2 2019

Aug 14, 2019

BUY
$62.09 - $86.14 $5.72 Million - $7.93 Million
92,068 Added 22.35%
503,942 $32.4 Million
Q1 2019

May 14, 2019

BUY
$52.92 - $81.17 $21.3 Million - $32.6 Million
402,227 Added 4169.45%
411,874 $33 Million
Q4 2018

Feb 14, 2019

SELL
$43.37 - $59.54 $128,331 - $176,178
-2,959 Reduced 23.47%
9,647 $522,000
Q3 2018

Nov 15, 2018

SELL
$42.88 - $53.7 $207,324 - $259,639
-4,835 Reduced 27.72%
12,606 $650,000
Q2 2018

Aug 14, 2018

BUY
$40.53 - $50.7 $1,094 - $1,368
27 Added 0.16%
17,441 $727,000
Q1 2018

May 15, 2018

SELL
$44.08 - $55.05 $35,837 - $44,755
-813 Reduced 4.46%
17,414 $768,000
Q4 2017

Feb 14, 2018

BUY
$50.3 - $64.39 $18,611 - $23,824
370 Added 2.07%
18,227 $917,000
Q3 2017

Nov 14, 2017

BUY
$45.56 - $59.57 $813,564 - $1.06 Million
17,857
17,857 $905,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.35B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.